Ardelyx, Inc. (NASDAQ:ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs, today announced that data supporting additional positive clinical observations of IBSRELA® (tenapanor) was presented at the 2024 Digestive Disease Week Conference (DDW), currently taking place in Washington, D.C. IBSRELA is a first-in-class treatment that is approved by the U.S. Food and Drug Administration to treat irritable bowel syndrome with constipation (IBS-C) in adults.
Ardelyx Presents Additional Data On IBSRELA, A First-In-Class Treatment For IBS-C In Adults At The 2024 Digestive Disease Week Conference
Company Profile
Tue. 21 May 2024, 8:27am ET
Benzinga
Biotech, News, General